X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

WHO Advocates For More Research For Long COVID Patients

Content Team by Content Team
16th September 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The WHO has urged nations to invest promptly in research, recovery, and rehabilitation in order to treat the post-COVID-19 syndrome seriously.

At least 17 million people in the 53 Member States of the WHO European Region may have encountered post-COVID-19 conditions, also known as long COVID, in the first two years of the pandemic, according to a new simulation done for WHO by the Institute for Health Metrics and Evaluation at the University of Washington School of Medicine in the US. Or, to put it another way, between 2020 and 2021, an estimated 17 million individuals matched the WHO definition of a new case of extended COVID with symptoms that lasted at least three months.

According to the model, the significant rise in verified COVID-19 instances from late 2020 through 2021 will be the main cause of the 307% surge of new long-term COVID cases found between 2020 and 2021.

Additionally, the modelling indicates that women are twice as likely as men to have a long COVID. Additionally, one in three females and one in five males are likely to develop protracted COVID in severe COVID-19 cases that require hospitalisation.

Dr. Hans Henri Kluge, WHO’s regional director for Europe, stated that while there is still much to learn about long-term COVID, particularly how it manifests in vaccinated versus unvaccinated communities and how it affects re-infections, these data highlight the urgent need for additional research, financing, assistance, and togetherness with those who suffer from this condition.

Millions of people in their region, which spans Central Asia and Europe, are still experiencing crippling symptoms months after contracting COVID-19. They can’t bear their suffering any longer. He added that governments and health stakeholders must work together to develop solutions that are supported by data and analysis.

The aggregate phrase post COVID-19 condition or long COVID refers to the collection of persistent symptoms that some patients endure after having COVID-19. While the majority of COVID-19 sufferers recover fully, it is suspected that 10–20% experience a range of short-, mid-, and long-term side effects, including fatigue, dyspnea, and cognitive impairment.

Long-term COVID can both directly and indirectly damage a person’s mental health as well as their capacity to carry out daily tasks like work or household chores.

Previous Post

Biden Aims To Boost US Biomanufacturing Under Chinese Threat

Next Post

BioMarin, CSL- Haemophilia Gene Treatments Win ICER Backing

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Forma Therapeutics To Be Acquired By Novo Nordisk For $1.1bn

BioMarin, CSL- Haemophilia Gene Treatments Win ICER Backing

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In